PubMed:12626384 / 128-411 JSONTXT

{"project":"sentences","denotations":[{"id":"TextSentencer_T2","span":{"begin":0,"end":105},"obj":"Sentence"},{"id":"TextSentencer_T3","span":{"begin":106,"end":283},"obj":"Sentence"},{"id":"T2","span":{"begin":0,"end":283},"obj":"Sentence"},{"id":"T2","span":{"begin":0,"end":105},"obj":"Sentence"},{"id":"T3","span":{"begin":106,"end":283},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Fabry disease is a lysosomal storage disease arising from deficiency of the enzyme alpha-galactosidase A. Two recombinant protein therapeutics, Fabrazyme (agalsidase beta) and Replagal (agalsidase alfa), have been approved in Europe as enzyme replacement therapies for Fabry disease."}

{"project":"GlycoBiology-FMA","denotations":[{"id":"_T3","span":{"begin":19,"end":28},"obj":"FMAID:63836"},{"id":"_T4","span":{"begin":19,"end":28},"obj":"FMAID:162299"},{"id":"_T5","span":{"begin":89,"end":102},"obj":"FMAID:196789"},{"id":"_T6","span":{"begin":89,"end":102},"obj":"FMAID:82794"},{"id":"_T7","span":{"begin":122,"end":129},"obj":"FMAID:67257"},{"id":"_T8","span":{"begin":122,"end":129},"obj":"FMAID:165447"}],"namespaces":[{"prefix":"FMAID","uri":"http://purl.org/sig/ont/fma/fma"}],"text":"Fabry disease is a lysosomal storage disease arising from deficiency of the enzyme alpha-galactosidase A. Two recombinant protein therapeutics, Fabrazyme (agalsidase beta) and Replagal (agalsidase alfa), have been approved in Europe as enzyme replacement therapies for Fabry disease."}

{"project":"uniprot-human","denotations":[{"id":"T1","span":{"begin":83,"end":104},"obj":"http://www.uniprot.org/uniprot/P06280"},{"id":"T2","span":{"begin":155,"end":165},"obj":"http://www.uniprot.org/uniprot/P06280"},{"id":"T3","span":{"begin":186,"end":196},"obj":"http://www.uniprot.org/uniprot/P06280"}],"text":"Fabry disease is a lysosomal storage disease arising from deficiency of the enzyme alpha-galactosidase A. Two recombinant protein therapeutics, Fabrazyme (agalsidase beta) and Replagal (agalsidase alfa), have been approved in Europe as enzyme replacement therapies for Fabry disease."}

{"project":"uniprot-mouse","denotations":[{"id":"T1","span":{"begin":83,"end":104},"obj":"http://www.uniprot.org/uniprot/P51569"}],"text":"Fabry disease is a lysosomal storage disease arising from deficiency of the enzyme alpha-galactosidase A. Two recombinant protein therapeutics, Fabrazyme (agalsidase beta) and Replagal (agalsidase alfa), have been approved in Europe as enzyme replacement therapies for Fabry disease."}

{"project":"GlycoBiology-NCBITAXON","denotations":[{"id":"T1","span":{"begin":166,"end":170},"obj":"http://purl.bioontology.org/ontology/NCBITAXON/3554"},{"id":"T2","span":{"begin":166,"end":170},"obj":"http://purl.bioontology.org/ontology/NCBITAXON/158455"}],"text":"Fabry disease is a lysosomal storage disease arising from deficiency of the enzyme alpha-galactosidase A. Two recombinant protein therapeutics, Fabrazyme (agalsidase beta) and Replagal (agalsidase alfa), have been approved in Europe as enzyme replacement therapies for Fabry disease."}

{"project":"GO-BP","denotations":[{"id":"T2","span":{"begin":29,"end":36},"obj":"http://purl.obolibrary.org/obo/GO_0051235"},{"id":"T4","span":{"begin":29,"end":36},"obj":"http://purl.obolibrary.org/obo/GO_0035732"},{"id":"T5","span":{"begin":83,"end":102},"obj":"http://purl.obolibrary.org/obo/GO_0004557"}],"text":"Fabry disease is a lysosomal storage disease arising from deficiency of the enzyme alpha-galactosidase A. Two recombinant protein therapeutics, Fabrazyme (agalsidase beta) and Replagal (agalsidase alfa), have been approved in Europe as enzyme replacement therapies for Fabry disease."}

{"project":"GO-CC","denotations":[{"id":"T1","span":{"begin":19,"end":28},"obj":"http://purl.obolibrary.org/obo/GO_0005764"}],"text":"Fabry disease is a lysosomal storage disease arising from deficiency of the enzyme alpha-galactosidase A. Two recombinant protein therapeutics, Fabrazyme (agalsidase beta) and Replagal (agalsidase alfa), have been approved in Europe as enzyme replacement therapies for Fabry disease."}

{"project":"EDAM-topics","denotations":[{"id":"T3","span":{"begin":6,"end":13},"obj":"http://edamontology.org/topic_0634"},{"id":"T4","span":{"begin":19,"end":28},"obj":"http://edamontology.org/topic_0616"},{"id":"T5","span":{"begin":37,"end":44},"obj":"http://edamontology.org/topic_0634"},{"id":"T6","span":{"begin":122,"end":129},"obj":"http://edamontology.org/topic_0078"},{"id":"T7","span":{"begin":275,"end":282},"obj":"http://edamontology.org/topic_0634"}],"text":"Fabry disease is a lysosomal storage disease arising from deficiency of the enzyme alpha-galactosidase A. Two recombinant protein therapeutics, Fabrazyme (agalsidase beta) and Replagal (agalsidase alfa), have been approved in Europe as enzyme replacement therapies for Fabry disease."}

{"project":"EDAM-DFO","denotations":[{"id":"T2","span":{"begin":122,"end":129},"obj":"http://edamontology.org/format_1208"},{"id":"T3","span":{"begin":122,"end":129},"obj":"http://edamontology.org/data_1467"}],"text":"Fabry disease is a lysosomal storage disease arising from deficiency of the enzyme alpha-galactosidase A. Two recombinant protein therapeutics, Fabrazyme (agalsidase beta) and Replagal (agalsidase alfa), have been approved in Europe as enzyme replacement therapies for Fabry disease."}

{"project":"DisGeNET5_gene_disease","denotations":[{"id":"12626384-1#83#104#gene2717","span":{"begin":83,"end":104},"obj":"gene2717"},{"id":"12626384-1#0#13#diseaseC0002986","span":{"begin":0,"end":13},"obj":"diseaseC0002986"},{"id":"12626384-1#19#44#diseaseC0085078","span":{"begin":19,"end":44},"obj":"diseaseC0085078"}],"relations":[{"id":"83#104#gene27170#13#diseaseC0002986","pred":"associated_with","subj":"12626384-1#83#104#gene2717","obj":"12626384-1#0#13#diseaseC0002986"},{"id":"83#104#gene271719#44#diseaseC0085078","pred":"associated_with","subj":"12626384-1#83#104#gene2717","obj":"12626384-1#19#44#diseaseC0085078"}],"text":"Fabry disease is a lysosomal storage disease arising from deficiency of the enzyme alpha-galactosidase A. Two recombinant protein therapeutics, Fabrazyme (agalsidase beta) and Replagal (agalsidase alfa), have been approved in Europe as enzyme replacement therapies for Fabry disease."}

{"project":"DisGeNET","denotations":[{"id":"T0","span":{"begin":83,"end":104},"obj":"gene:2717"},{"id":"T1","span":{"begin":0,"end":13},"obj":"disease:C0002986"},{"id":"T2","span":{"begin":83,"end":104},"obj":"gene:2717"},{"id":"T3","span":{"begin":19,"end":44},"obj":"disease:C0085078"}],"relations":[{"id":"R1","pred":"associated_with","subj":"T0","obj":"T1"},{"id":"R2","pred":"associated_with","subj":"T2","obj":"T3"}],"namespaces":[{"prefix":"gene","uri":"http://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"disease","uri":"http://purl.bioontology.org/ontology/MEDLINEPLUS/"}],"text":"Fabry disease is a lysosomal storage disease arising from deficiency of the enzyme alpha-galactosidase A. Two recombinant protein therapeutics, Fabrazyme (agalsidase beta) and Replagal (agalsidase alfa), have been approved in Europe as enzyme replacement therapies for Fabry disease."}

{"project":"mondo_disease","denotations":[{"id":"T2","span":{"begin":0,"end":13},"obj":"Disease"},{"id":"T3","span":{"begin":19,"end":44},"obj":"Disease"},{"id":"T4","span":{"begin":269,"end":282},"obj":"Disease"}],"attributes":[{"id":"A2","pred":"mondo_id","subj":"T2","obj":"http://purl.obolibrary.org/obo/MONDO_0010526"},{"id":"A3","pred":"mondo_id","subj":"T3","obj":"http://purl.obolibrary.org/obo/MONDO_0002561"},{"id":"A4","pred":"mondo_id","subj":"T4","obj":"http://purl.obolibrary.org/obo/MONDO_0010526"}],"text":"Fabry disease is a lysosomal storage disease arising from deficiency of the enzyme alpha-galactosidase A. Two recombinant protein therapeutics, Fabrazyme (agalsidase beta) and Replagal (agalsidase alfa), have been approved in Europe as enzyme replacement therapies for Fabry disease."}